Anything is possible regarding other applications but I think breast cancer reconstructions is the main one, I'm not sure that the augmentation market is part of their strategy. I'm guessing but, as no tissue is removed during an augmentation there is likely to be enough tissue to accommodate an implant. Whereas with mastectomy all/some of the breast tissue and skin is removed, so expansion is usually necessary to accommodate the eventual implant/flap.
I agree with your val, 20%+ market share should be possible, in which case the SP could be a multiple of where it is currently, though I think it will take a bit longer than the 6 months it took in Aus, maybe 12-18 months, as the US population is less concentrated in a few main cities and the volume of training of staff, surgeons and supply required will be that much greater.
AXP Price at posting:
$1.08 Sentiment: Buy Disclosure: Held
(20min delay)
